BR0315846A - Tratamento farmacológico para apnéia do sono - Google Patents
Tratamento farmacológico para apnéia do sonoInfo
- Publication number
- BR0315846A BR0315846A BR0315846-2A BR0315846A BR0315846A BR 0315846 A BR0315846 A BR 0315846A BR 0315846 A BR0315846 A BR 0315846A BR 0315846 A BR0315846 A BR 0315846A
- Authority
- BR
- Brazil
- Prior art keywords
- sleep apnea
- pharmacological treatment
- pharmacological
- agents
- sleep
- Prior art date
Links
- 238000011458 pharmacological treatment Methods 0.000 title abstract 2
- 201000002859 sleep apnea Diseases 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"TRATAMENTO FARMACOLóGICO PARA APNéIA DO SONO". A presente invenção se relaciona de forma geral a métodos farmacológicos para a prevenção ou melhoria de distúrbios respiratórios relacionados ao sono por meio da administração de agentes ou combinações de agentes que possuem atividade farmacológica relacionada a serotonina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/285,277 US7160898B2 (en) | 2001-12-14 | 2002-10-31 | Pharmacological treatment for sleep apnea |
PCT/US2003/034592 WO2004041272A2 (en) | 2002-10-31 | 2003-10-29 | Use of serotonin receptor antagonists for the treatment of sleep apnea |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315846A true BR0315846A (pt) | 2005-09-27 |
Family
ID=32312044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315846-2A BR0315846A (pt) | 2002-10-31 | 2003-10-29 | Tratamento farmacológico para apnéia do sono |
Country Status (11)
Country | Link |
---|---|
US (4) | US7160898B2 (pt) |
EP (1) | EP1572202A2 (pt) |
JP (2) | JP2006511502A (pt) |
CN (1) | CN1708302A (pt) |
AU (1) | AU2003301824B2 (pt) |
BR (1) | BR0315846A (pt) |
CA (1) | CA2503718C (pt) |
MX (1) | MXPA05004448A (pt) |
NO (1) | NO20052420L (pt) |
NZ (1) | NZ539602A (pt) |
WO (1) | WO2004041272A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
EP1181015A2 (en) * | 1999-03-01 | 2002-02-27 | Sepracor Inc. | Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
JP2007504181A (ja) * | 2003-09-04 | 2007-03-01 | ハー・ルンドベック・アクチエゼルスカベット | セロトニン再取り込み阻害剤およびロキサピンの併用 |
US8470846B2 (en) * | 2004-04-30 | 2013-06-25 | National University Corporation Chiba University | Remedy for psychoneurotic diseases |
NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
EP1833467B1 (en) * | 2004-12-20 | 2016-08-03 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
EP1868602A1 (en) * | 2005-04-15 | 2007-12-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
WO2007047576A1 (en) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders |
WO2007098200A2 (en) * | 2006-02-16 | 2007-08-30 | Imthera Medical, Inc. | An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
RU2009141168A (ru) * | 2007-04-09 | 2011-05-20 | Сепракор Инк. (Us) | Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна |
CN101939043A (zh) | 2007-10-09 | 2011-01-05 | 伊姆特拉医疗公司 | 用于选择性刺激的装置、***和方法 |
AU2009302591B2 (en) | 2008-10-09 | 2014-08-07 | Imthera Medical, Inc. | Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
US20110112601A1 (en) | 2009-11-10 | 2011-05-12 | Imthera Medical, Inc. | System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
KR20130053921A (ko) * | 2011-11-16 | 2013-05-24 | 엘지전자 주식회사 | 도어 개방 유닛을 구비하는 냉장고 |
WO2017031319A1 (en) * | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
EP3361538B1 (en) * | 2015-10-06 | 2021-04-07 | Nissan Motor Co., Ltd. | Fuel cell stack |
US11844605B2 (en) | 2016-11-10 | 2023-12-19 | The Research Foundation For Suny | System, method and biomarkers for airway obstruction |
MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
WO2022182602A2 (en) * | 2021-02-24 | 2022-09-01 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075290A (en) * | 1989-06-28 | 1991-12-24 | University Of Virginia Alumni Patents Foundation | Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring |
IL97054A (en) | 1990-02-12 | 1995-10-31 | Bristol Meyers Squibb Co | Pharmaceutical preparations containing bospirone for the treatment of coma |
IL97053A (en) | 1990-02-12 | 1995-10-31 | Bristol Meyers Squibb Co | Pharmaceutical preparations containing azapyrone for the treatment of coma |
US6432956B1 (en) * | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
US5082665A (en) * | 1990-03-15 | 1992-01-21 | Tom Verny | Anti-snoring formulations using yohimbine |
US5356934A (en) * | 1990-03-29 | 1994-10-18 | Eli Lilly And Company | Selected serotonin subtype receptor agonist to treat sleep apnea |
JPH04184233A (ja) * | 1990-11-19 | 1992-07-01 | Matsushita Electric Ind Co Ltd | 圧力センサ |
US5166158A (en) * | 1990-12-20 | 1992-11-24 | The University Of Tennessee Research Corporation | Method for the treatment of apnea and/or bradycardia |
EP0517984A1 (en) | 1991-06-11 | 1992-12-16 | Merrell Dow Pharmaceuticals Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
FR2706767B1 (pt) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
GB9613969D0 (en) * | 1996-07-03 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
US6030992A (en) * | 1997-02-26 | 2000-02-29 | Eli Lilly And Company | Methods of treating or preventing sleep apnea |
FR2765107B1 (fr) * | 1997-06-26 | 2000-03-24 | Sanofi Sa | Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil |
PT1030667E (pt) * | 1997-11-14 | 2005-06-30 | Akzo Nobel Nv | Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono |
PT1066036E (pt) * | 1998-02-27 | 2006-09-29 | Univ Illinois | Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono |
US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
AU3891299A (en) * | 1998-05-21 | 1999-12-06 | Eli Lilly And Company | Combination therapy for treatment of depression |
NZ535055A (en) | 1998-06-15 | 2006-04-28 | Sepracor Inc | Use of optically pure (-) norcisapride in the treatment of apnea, and other disorders |
CN1312717A (zh) * | 1998-06-15 | 2001-09-12 | 塞普拉科有限公司 | 光学纯度(+)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途 |
EP1181015A2 (en) * | 1999-03-01 | 2002-02-27 | Sepracor Inc. | Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron |
GB9930077D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
AU2002212888A1 (en) | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
-
2002
- 2002-10-31 US US10/285,277 patent/US7160898B2/en not_active Expired - Fee Related
-
2003
- 2003-10-29 WO PCT/US2003/034592 patent/WO2004041272A2/en active Application Filing
- 2003-10-29 BR BR0315846-2A patent/BR0315846A/pt not_active Application Discontinuation
- 2003-10-29 CN CNA200380102535XA patent/CN1708302A/zh active Pending
- 2003-10-29 AU AU2003301824A patent/AU2003301824B2/en not_active Ceased
- 2003-10-29 MX MXPA05004448A patent/MXPA05004448A/es active IP Right Grant
- 2003-10-29 CA CA002503718A patent/CA2503718C/en not_active Expired - Fee Related
- 2003-10-29 JP JP2004550292A patent/JP2006511502A/ja active Pending
- 2003-10-29 NZ NZ539602A patent/NZ539602A/en unknown
- 2003-10-29 EP EP03810822A patent/EP1572202A2/en not_active Withdrawn
-
2005
- 2005-05-19 NO NO20052420A patent/NO20052420L/no not_active Application Discontinuation
-
2006
- 2006-12-21 US US11/643,238 patent/US20070123517A1/en not_active Abandoned
-
2008
- 2008-09-11 US US12/208,482 patent/US20090005357A1/en not_active Abandoned
-
2010
- 2010-05-11 JP JP2010109025A patent/JP2010168404A/ja active Pending
-
2012
- 2012-01-06 US US13/345,066 patent/US20120108570A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2503718A1 (en) | 2004-05-21 |
US7160898B2 (en) | 2007-01-09 |
JP2010168404A (ja) | 2010-08-05 |
EP1572202A2 (en) | 2005-09-14 |
AU2003301824A1 (en) | 2004-06-07 |
US20120108570A1 (en) | 2012-05-03 |
US20070123517A1 (en) | 2007-05-31 |
MXPA05004448A (es) | 2005-11-23 |
CN1708302A (zh) | 2005-12-14 |
WO2004041272A2 (en) | 2004-05-21 |
CA2503718C (en) | 2009-07-14 |
WO2004041272A3 (en) | 2004-09-16 |
NO20052420D0 (no) | 2005-05-19 |
AU2003301824B2 (en) | 2008-09-04 |
US20030130266A1 (en) | 2003-07-10 |
JP2006511502A (ja) | 2006-04-06 |
US20090005357A1 (en) | 2009-01-01 |
NO20052420L (no) | 2005-06-23 |
NZ539602A (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315846A (pt) | Tratamento farmacológico para apnéia do sono | |
CY1105729T1 (el) | Παραγοντες με σχετιζομενη με σεροτονινη δραση για την αντιμετωπιση για υπνικη απνοια | |
BR0116201A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o composto, utilização do composto, processo para o tratamento e profilaxia de distúrbios e para o tratamento de obesidade | |
DE60114929D1 (de) | Nasenmaske | |
BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
YU35503A (sh) | Nove kompozicije lekova bazirane na solima tiotropijuma i solima salmeterola | |
MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
BR0209992A (pt) | Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias | |
BR0309185A (pt) | Medicamento contendo beta-miméticos e um novo anticolinérgico | |
BR0208111A (pt) | Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade | |
MY135838A (en) | Methods for the treatment of mental disorders | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
FR2784298B1 (fr) | Masque respiratoire nasal destine aux traitements des troubles respiratoires, notamment de l'apnee du sommeil | |
PT1261333E (pt) | Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico | |
BR0317586A (pt) | Compostos para normalização do ciclo sono/vigìlia | |
HK1081861A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
BR0010006A (pt) | Utilização do saredutante e de seus sais farmaceuticamente aceitáveis para o preparo de medicamentos úteis no tratamento ou na prevenção do conjunto das perturbações do humor, das perturbações da adaptação ou das perturbações mistas ansiedade-depressão | |
WO2007035879A3 (en) | Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm | |
BR0009080A (pt) | Método de tratamento da apnéia do sono | |
MXPA04002401A (es) | Nuevos medicamentos para inhalacion. | |
AU2003294100A8 (en) | Use of hyaluronic acid for respiratory disorders or the upper airways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |